Pulmonx (NASDAQ:LUNG – Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.
Pulmonx (NASDAQ:LUNG – Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. Pulmonx had a negative net margin of 88.60% and a negative return on equity of 46.63%. The company had revenue of $19.30 million during the quarter, compared to the consensus estimate of $18.24 million. During the same quarter in the prior year, the firm posted ($0.38) EPS. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Pulmonx Stock Performance
Shares of Pulmonx stock opened at $7.50 on Tuesday. The company has a 50 day moving average of $8.92 and a 200-day moving average of $10.72. Pulmonx has a 1-year low of $7.11 and a 1-year high of $14.84. The company has a current ratio of 6.50, a quick ratio of 5.77 and a debt-to-equity ratio of 0.30. The company has a market cap of $289.05 million, a PE ratio of -4.69 and a beta of 0.60.
Insider Buying and Selling at Pulmonx
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on LUNG shares. Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price objective (down previously from $16.00) on shares of Pulmonx in a research note on Friday, February 23rd. Piper Sandler reissued an “overweight” rating and issued a $17.00 price objective on shares of Pulmonx in a research note on Wednesday, April 3rd. Citigroup increased their price objective on shares of Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus increased their price objective on shares of Pulmonx from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Pulmonx presently has an average rating of “Moderate Buy” and an average target price of $15.83.
Check Out Our Latest Report on Pulmonx
Pulmonx Company Profile
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
See Also
- Five stocks we like better than Pulmonx
- Golden Cross Stocks: Pattern, Examples and Charts
- The 3 Hottest Insiders Buys This Month
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- What is the Dogs of the Dow Strategy? Overview and Examples
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.